Neuphoria Therapeutics extends rights agreement through October 2027

Neuphoria Therapeutics Inc. has extended the final expiration date of its rights agreement to October 27, 2027, a move approved by the company's Board of Directors on October 23, 2026. The Delaware-based corporation filed an amendment to its existing agreement with Computershare Trust Company, N.A., which serves as the rights agent. The extension applies unless the agreement is earlier extended, modified, or terminated.

The company, which trades on The Nasdaq Stock Market, LLC under the ticker symbol NEUP, reported the development in a Form 8-K filed with the U.S. Securities and Exchange Commission. The filing indicates that the amendment modifies the original rights agreement dated October 27, 2025. Under the terms of Amendment No. 1, the rights remain subject to the provisions of the original agreement, except as specifically amended. The company noted that the description provided in the filing is qualified by reference to the full text of both the original agreement and the new amendment.

Spyridon Papapetropoulos, the interim Chief Executive Officer of Neuphoria Therapeutics, signed the report on behalf of the registrant. The document includes references to exhibits that detail the specific terms of the rights agreement and the amendment. These exhibits are incorporated by reference into the filing to provide complete legal context for security holders. The company's principal executive offices are located in Millis, Massachusetts.

This modification affects the timeline for the rights associated with the company's common stock, which has a par value of $0.00001 per share. The filing also addresses Item 3.03 regarding material modifications to rights of security holders, incorporating the information from Item 1.01 by reference. The extension ensures that the rights agreement remains in effect for an additional year beyond its previous scheduled expiration date.